Evidence map›Paper›PMID 25922835›Full record

ArticleBioMed research international2015

Antiresistin RNA Oligonucleotide Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease in Mice through Attenuating Proinflammatory Cytokines.

Yi Tan, Xing Liang Jin, Weiguo Lao, Jane Kim, Linda Xiao, Xianqin Qu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Efficacy of Probiotic StrainsPharmaceuticals (Basel, Switzerland) · 2024
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yi TanSchool of Medical & Molecular Biosciences, University of Technology Sydney, Sydney, NSW 2007, Australia.
Xing Liang JinSchool of Medical & Molecular Biosciences, University of Technology Sydney, Sydney, NSW 2007, Australia.
Weiguo LaoSchool of Medical & Molecular Biosciences, University of Technology Sydney, Sydney, NSW 2007, Australia.
Jane KimSchool of Medical & Molecular Biosciences, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0003-1408-5984
Linda XiaoSchool of Medical & Molecular Biosciences, University of Technology Sydney, Sydney, NSW 2007, Australia.
Xianqin QuSchool of Medical & Molecular Biosciences, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-8260-2384
University of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to determine whether inhibition of resistin by a synthetic antiresistin RNA (oligonucleotide) oligo ameliorates metabolic and histological abnormalities in nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD) in mice. The antiresistin RNA oligo and a scrambled control oligo (25 mg/kg of body weight) were i.p. injected to HFD mice. Serum metabolic parameters and hepatic enzymes were measured after 4-week treatment. The treatment significantly reduced epididymal fat and attenuated the elevated serum resistin, cholesterol, triglycerides, glucose, and insulin with an improved glucose tolerance test. Antiresistin RNA oligo also normalized serum AST and ALT levels with improved pathohistology of NAFLD. Immunoblotting and qRT-PCR revealed that decreased protein and mRNA expression of resistin in fat and liver tissues of the treated mice were associated with reduction of adipose TNF-α and IL-6 expression and secretion into circulation. mRNA and protein expression of hepatic phosphoenolpyruvate carboxykinase (PEPCK) and sterol regulatory element-binding protein-1c (SREBP-1c) were also significantly decreased in the treated mice. Our results suggest that resistin may exacerbate NAFLD in metabolic syndrome through upregulating inflammatory cytokines and hepatic PEPCK and SREBP-1c. Antiresistin RNA oligo ameliorated metabolic abnormalities and histopathology of NAFLD through attenuating proinflammatory cytokines.

Indexed as

AnimalsDiet, High-FatGene Expression RegulationInsulin ResistanceInterleukin-6MiceNon-alcoholic Fatty Liver DiseaseObesityOligonucleotidesPhosphoenolpyruvate Carboxykinase (ATP)ResistinRNASterol Regulatory Element Binding Protein 1Tumor Necrosis Factor-alphaInterleukin-6OligonucleotidesPCK2 protein, humanPhosphoenolpyruvate Carboxykinase (ATP)ResistinRetn protein, mouseRNASrebf1 protein, mouseSterol Regulatory Element Binding Protein 1Tumor Necrosis Factor-alpha

Identifiers

PMID25922835
PMCPMC4397480
OpenAlexW1979717496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.